Impact Biomedical IBO
NYSE IBO
$0.48 +0.03 (+6.83%)
As of: Aug 21, 2026 · 2:19 PM EDT

Impact Biomedical (IBO) Selling, General & Administrative (2022 - 2026)

Impact Biomedical (IBO) Selling, General & Administrative (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) SG&A (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 582.20 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 662.10 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 1.13 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 216.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 593.21 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 347.92 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -196.26 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 247.47 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 161.89 Mn
10 Impact Biomedical 49.54 Mn 49.53 Mn 2,000.00 167,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 167,000.00
Mar 31, 2026 1.62 Mn
Dec 31, 2025 -443,000.00
Sep 30, 2025 261,000.00
Jun 30, 2025 246,000.00
Mar 31, 2025 248,000.00
Dec 31, 2024 -67,000.00
Sep 30, 2024 132,000.00
Jun 30, 2024 145,000.00
Mar 31, 2024 148,000.00
Dec 31, 2023 133,000.00
Sep 30, 2023 101,000.00
Jun 30, 2023 41,000.00
Mar 31, 2023 40,000.00
Dec 31, 2022 39,000.00
Sep 30, 2022 90,000.00
Jun 30, 2022 58,000.00